Written Question·Department of Health and Social Care·UIN 116002

Rare Cancers: Medical Treatments

Tabled: 25 February 2026

Answered: 4 March 2026

Question

Clive Jones

To ask the Secretary of State for Health and Social Care, whether the joint accelerated approvals pathway operated by the National Institute for Health and Care Excellence and Medicines and Healthcare products Regulatory Agency will enable tumour-agnostic

Answer

Dr Zubir Ahmed

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are working to deliver the Government’s ambitions, as set out in the 10-Year Health Plan for England and the Life Sciences Sect...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 116002) →